Recursion expands TUPELO study eligibility, in FDA talks on REC-4881 registration pathway

Recursion Pharmaceuticals expanded eligibility for its Phase Ib/II TUPELO study of REC-4881 to adults 18 and older with an alternative dosing cohort, and is in FDA discussions on a potential registration pathway in FAP, targeting a registrational study in H2 2027.

Detected & updated continuously · Source: Nebula